Free shipping on all orders over $ 500


Cat. No. M6153
E6005 Structure


Size Price Availability Quantity
5mg USD 99  USD110 In stock
10mg USD 162  USD180 In stock
50mg USD 540  USD600 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control
  • Current batch:
  • Purity >98%
  • COA
  • MSDS
Biological Activity

In vitro: RVT-501 potently and selectively inhibits human PDE4 activity with an IC50 of 2.8 nM and suppresses the production of various cytokines from human lymphocytes and monocytes with IC50 values ranging from 0.49 to 3.1 nM.

In vivo: RVT-501 is currently in phase 2 development for patients with mild-to-moderate atopic dermatitis. In mice models, the topical application of RVT-501 produces an immediate antipruritic effect as well as an anti-inflammatory effect with reduced expression of cytokines/adhesion molecules. On the basis of these observed effects, topical RVT-501 ameliorates the appearance of atopic dermatitis-like skin lesions in two types of AD models, hapten- and mite-elicited models, exhibiting inhibitory effects comparable to that of tacrolimus.

Cell Experiment
Cell lines
Preparation method
Incubation time
Animal Experiment
Animal models NC/Nga mice
Formulation 4% SDS solution
Dosages 10 μl/g
Administration s.c.
Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Chemical Information
Molecular Weight 472.49
Formula C26H24N4O5
CAS Number 947620-48-6
Purity >98%
Solubility 100 mg/mL in DMSO
Storage at -20°C

Validation of a UPLC-MS/MS method for the simultaneous determination of E6005, a phosphodiesterase 4 inhibitor, and its metabolite in human plasma.
Mano Y, et al. J Chromatogr B Analyt Technol Biomed Life Sci. 2015 Aug 15;998-999:31-9. PMID: 26149248.

Antipruritic effect of the topical phosphodiesterase 4 inhibitor E6005 ameliorates skin lesions in a mouse atopic dermatitis model.
Ishii N, et al. J Pharmacol Exp Ther. 2013 Jul;346(1):105-12. PMID: 23674603.

Related PDE Products

Vesnarinone is a cardiotonic agent, mixed phosphodiesterase 3 inhibitor and ion-channel modifier that has modest, dose-dependent, positive inotropic activity.

Roflumilast N-oxide

Roflumilast N-oxide is a phosphodiesterase 4 inhibitor.


CP671305 is a potent and selective, orally active inhibitor of phosphodiesterase-4-D with high activities.

ITI-214 phosphate

ITI-214 phosphate is an orally active, potent and selective inhibitors of PDE1, exhibits potent PDE1 inhibitory activity (Ki = 58 pM).


IBMX is a pDE inhibitor (non-selective) with IC50 values of 6.5±1.2, 26.3±3.9 and 31.7±5.3 μM for PDE3, 4 and 5 respectively.

Abmole Inhibitor Catalog 2017

Keywords: E6005, RVT-501 supplier, PDE, inhibitors

Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.